Pharmacokinetics and side-effects of gentamicin in healthy and pseudomonas aeruginosa infected sheep.

J Vet Pharmacol Ther

Faculty of Veterinary Medicine, Department of Pharmacology, Toxicology and Therapeutics, Thrakia University, 6000 Stara Zagora, Bulgaria.

Published: June 2001

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2885.2001.00332.xDOI Listing

Publication Analysis

Top Keywords

pharmacokinetics side-effects
4
side-effects gentamicin
4
gentamicin healthy
4
healthy pseudomonas
4
pseudomonas aeruginosa
4
aeruginosa infected
4
infected sheep
4
pharmacokinetics
1
gentamicin
1
healthy
1

Similar Publications

Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.

Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).

View Article and Find Full Text PDF

Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance.

J Med Chem

January 2025

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.

Fibroblast growth factor receptors (FGFRs) are established oncogenic drivers in various solid tumors. However, the approved FGFR inhibitors face challenges with acquired resistance and dose-limiting adverse effects associated with FGFR1/4 inhibition, limiting therapeutic efficacy. Herein, we systematically explored linker and electrophile moieties based on the pyrrolopyrazine carboxamide core and identified aniline α-fluoroacrylamide as an effective covalent warhead.

View Article and Find Full Text PDF

Withania somnifera-derived phytochemicals as Bcl-B inhibitors in cancer therapy: A computational approach from byte to bench to bedside.

Biochem Biophys Res Commun

January 2025

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida, India. Electronic address:

Cancer is the second foremost cause of fatalities associated with non-communicable diseases across the globe, affecting multiple organs and often necessitating costly treatments with adverse side effects. Apoptosis, the body's natural cell death process, plays a crucial role in the prevention of cancer, but it's often disrupted in cancer cells, allowing uncontrolled proliferation. Restoring apoptosis in cancer cells is one of the promising therapeutic strategies to curb tumor growth and enhance clinical outcomes.

View Article and Find Full Text PDF

Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.

Expert Opin Pharmacother

January 2025

Mediprobe Research Inc, London, ON, Canada.

Introduction: Alopecia affects many individuals, with androgenetic alopecia (AGA) being the most common form in both men and women. The exact etiology of AGA is unclear. The systemic treatments of AGA include 5-alpha reductase inhibitors (finasteride, dutasteride), low-dose oral minoxidil.

View Article and Find Full Text PDF

A middle childhood boy with epilepsy exhibited persistent low concentrations of valproic acid, lamotrigine and topiramate for over 1 month, primarily due to pharmacokinetic interactions involving fosphenytoin, meropenem and phenobarbital. Awareness of these clinically significant interactions is crucial for ensuring effective seizure control. However, further research is needed to establish optimal evidence-based treatment strategies in complex paediatric cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!